A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
| 対象疾患 | Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic |
|---|---|
| 相 | 第2相 |
| スポンサー | University of Iowa |
| ステータス | 完了 |
| 参加者数 | 40 名 |
| 介入（薬剤） | Gemcitabine, nab-paclitaxel, Pharmacological ascorbate |
| 開始日 | 2018年11月28日 |
| 完了日 | 2024年8月26日 |
| 結果公開日 | 2026年7月23日 |
概要
This clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for metastatic pancreatic adenocarcinoma (a type of pancreatic cancer). Subjects are randomized between a control group (standard treatment) and an intervention group (pharmacologic ascorbate in addition to the standard treatment).
Overall Survival
| Ascorbate Group | 16 months |
|---|---|
| Control | 8.3 months |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroqu — Massachusetts General Hospital
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group